Rayno Biobeat 2017 #1: Biotech Rally Driven By M&A
Update-1... 1:45p EST Biotech Rally Biogen (BIIB) looking good in here at $275+, up 4.2% over five days, down 2.7% YTD. IBB and XBI slight gains. ======== Biotech Rally Takes Levels to January Top IBB up 1% to $284.56, up 7.2% YTD XBI up 1.79% to $67.07, up 13.3% YTD, a new high for 2017 but...
More Drug Pricing Headwinds for Biotech Just as Tape Improves: Update-1 M&A Uptick
Update 2/8/17 12N EST Biotech Stocks Perk Up on M&A Rumors PARP Inhibitor stocks- Clovis Oncology (CLVS) up 3%, Tesaro (TSRO) up 12.5%. IBB and XBI flattish. EXEL up 2.7%. INCY up 1.78%. GWPH up 3.9%. Also Foundation Medicine (FMI) is up over 10% to $24 with no news. GILD down 9.7% to $66:...
Large Cap Biopharma: January’17 Update-2
2/6/17 1 PM EST Mid-Caps Outperform in 2017 We will update the metrics and performance of "Large Cap Biopharma" after earnings from Gilead Sciences (GILD) and Regeneron (REGN) tomorrow. The XBI is up 11% YTD. The IBB is up 6.3% YTD. Merck (MRK) leads all large cap biotechs up 9.5% YTD. Among...
Biotech Blahs Worsened By Political Distractions…Updates
Update: 1/31/17 Biotechs rallying in midday trading afterTrump meeting. Looks like a good time to add positions like CELG IBB and XBI. Mid-Caps are strong-ALNY TSRO SGEN. Dx and Tools- DHR TMO good earnings. Update: After Close 5P 1/30/17 IBB down 1.35%, XBI down 1.73%, NAZ down 0.83% An...
Notes from J.P.Morgan Conference 2017: Sequencing (NGS) Moves to Toward Clinical Diagnostic Solutions
Outlook and Issues for Application of NGS for Clinical Diagnostics We heard a few presentations on NGS solutions and still think it is an important growth market for clinical diagnostics in oncology, rare diseases transplant medicine and NIPT. Gene sequencing (NGS) can lead to a better...